Embecta

Embecta Gross Profit

The Gross Profit of Embecta (EMBC) as of Oct 17, 2026 is 679.50 M USD. In the previous year, Gross Profit was 728.90 M USD — a change of -6.78% (lower).

Gross Profit

679.50 MUSD

YoY

-6.78%

Last updated:

Gross Profit of Embecta is 2025 679.50 M USD. Gross Profit of Embecta was 2024 728.90 M USD. It decreases by -6.78% lower compared to the previous year.

The Embecta Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2019
786.00 M USD
Jan 1, 2020
763.00 M USD
Jan 1, 2021
800.00 M USD
Jan 1, 2022
774.90 M USD
Jan 1, 2023
749.90 M USD
Jan 1, 2024
728.90 M USD
Jan 1, 2025
679.50 M USD
The Embecta Gross Profit history
YEARGross ProfitYoY
679.50 MUSD-6.78%
728.90 MUSD-2.80%
749.90 MUSD-3.23%
774.90 MUSD-3.14%
800.00 MUSD+4.85%
763.00 MUSD-2.93%
786.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Revenue

Embecta Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.12 B USD
229.60 M USD
70.40 M USD
Jan 1, 2024
1.12 B USD
156.50 M USD
78.30 M USD
Jan 1, 2025
1.08 B USD
329.30 M USD
95.40 M USD
Jan 1, 2026 (e)
1.02 B USD
240.70 M USD
108.67 M USD
Jan 1, 2027 (e)
1.07 B USD
236.26 M USD
104.38 M USD
Jan 1, 2028 (e)
1.09 B USD
240.06 M USD
115.48 M USD
Jan 1, 2029 (e)
1.09 B USD
322.82 M USD
175.29 M USD
Jan 1, 2030 (e)
1.09 B USD
330.05 M USD
181.21 M USD

Embecta Margins

Embecta stock margins

The Embecta margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Embecta. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Embecta.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
66.91 %
20.49 %
6.28 %
Jan 1, 2024
64.90 %
13.93 %
6.97 %
Jan 1, 2025
62.89 %
30.48 %
8.83 %
Jan 1, 2026 (e)
62.89 %
23.55 %
10.63 %
Jan 1, 2027 (e)
62.89 %
22.16 %
9.79 %
Jan 1, 2028 (e)
62.89 %
22.08 %
10.62 %
Jan 1, 2029 (e)
62.89 %
29.62 %
16.08 %
Jan 1, 2030 (e)
62.89 %
30.17 %
16.56 %

Embecta Stock analysis

What does Embecta do? Embecta Corp, headquartered in Parsippany, New Jersey, operates in the Health Care sector, manufacturing and distributing medical devices for diabetes treatment. The company employs 1,850 full-time staff and offers a portfolio including pen needles, syringes, safety injection devices, and a digital application for diabetes management. Its products, such as sterile single-use pen needles and safety pen needles with automatic shields, are designed to enhance user safety and convenience. Embecta distributes through retail, hospital, pharmacy, and institutional channels. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Gross Profit of Embecta is 679.50 M USD in 2025.

Gross Profit of Embecta changed from 728.90 M USD to 679.50 M USD, representing a -6.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Embecta since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Embecta

All Key Metrics — Embecta